Page last updated: 2024-08-21

pyrazines and paclitaxel

pyrazines has been researched along with paclitaxel in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (2.44)	18.7374
1990's	2 (4.88)	18.2507
2000's	18 (43.90)	29.6817
2010's	17 (41.46)	24.3611
2020's	3 (7.32)	2.80

Authors

Authors	Studies
Hamel, E; Lin, CM	1
Braguer, D; Briand, C; Carles, G; Garcia, P	2
Blagosklonny, MV	1
Daud, A; Munster, P; Spriggs, DR	1
Abbruzzese, JL; Chiao, PJ; Dong, QG; Evans, DB; Fujioka, S; McDonnell, TJ; Peng, B; Schmidt, C; Sclabas, GM; Tsao, MS; Wu, T	1
An, J; Fisher, M; Rettig, MB; Sun, Y	1
An, J; Fisher, M; Rettig, MB	1
Belani, CP	1
Adams, JM; Beaudoin, B; Bouillet, P; Degenhardt, K; Nelson, DA; Nieves-Neira, W; Tan, TT; Villunger, A; White, E	1
Edelman, MJ	1
Bradbury, J	1
Lilenbaum, R; Raez, LE	1
Soria, JC	1
Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ	1
Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, NR; Hauge, MD; Jaslowski, AJ; Jatoi, A; Ma, C; Moore, DF; Rowland, KM; Stella, PJ; Thomas, SP	1
Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L	1
Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M	1
Brüning, A; Burger, P; Burges, A; Friese, K; Lenhard, M; Rahmeh, M; Vogel, M	1
Fan, LS; Hu, Y; Kong, FF; Li, Y; Ma, D; Song, XH; Wang, SX; Weng, DH; Xing, H	1
Cao, X; Garofalo, A; Grande, F; Louie, S; Neamati, N; Oshima, T; Yamada, R	1
Bedor, M; Burrows, W; Edelman, MJ; Krasna, MJ; Smith, R; Suntharalingam, M	1
Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC	1
Albertini, M; Croghan, GA; Eckardt, J; Erlichman, C; Flaherty, L; Linette, G; Ma, C; Maples, WJ; Markovic, SN; Suman, VJ	1
Bossi, M; Canta, A; Carozzi, VA; Cavaletti, G; Chiorazzi, A; Marmiroli, P; Meregalli, C; Oggioni, N; Sala, B	1
Gounder, M; Kane, M; Karantza, V; Levinson, K; Lin, H; Lin, Y; Mehnert, JM; Moss, R; Poplin, E; Rubin, EH; Shih, WJ; Sovak, M; Stein, MN; Tan, AR; White, E	1
Fujii, T; Hiraike, H; Kawana, K; Kozuma, S; Miyamoto, Y; Nagasaka, K; Nakagawa, K; Nakagawa, S; Oda, K; Seiki, T; Sone, K; Taketani, Y; Tanikawa, M; Wada-Hiraike, O; Yano, T	1
Egashira, N; Oishi, R	1
Bennett, GJ; Bryant, L; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Ryerse, J; Salvemini, D	1
Dalton, HJ; Hu, W; Huang, J; Ivan, C; Jennings, NB; Kang, Y; Liu, J; Liu, T; Lu, C; Miyake, T; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Taylor, M; Wen, Y; Wu, SY; Zand, B	1
Annunziata, CM; Kohn, EC	1
Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL	1
Höke, A; Ray, M	1
Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Robey, RW; Shukla, S; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK	1
Balkaya, M; Boehmerle, W; Endres, M; Huehnchen, P; Peruzzaro, S	1
Adjei, AA; Aubry, MC; Bearden, JD; Foster, NR; Johnson, DB; Mandrekar, SJ; Mattar, BI; Meyers, JP; Molina, JR; Northfelt, DW; Rowland, KM; Schild, SE; Thomas, SP; Zhao, Y	1
Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G	1
Resham, K; Sharma, SS	1
Furukawa, Y; Ito, R; Iwama, A; Iwano, S; Kayamori, K; Koide, S; Lennox, W; Mimura, N; Miyawaki, A; Nagai, Y; Nakajima-Takagi, Y; Oshima, M; Sakaida, E; Sheedy, J; Shinoda, D; Tohyama, K; Weetall, M; Yamaguchi, K; Yamazaki, S; Zhong, C	1
Sakai, M; Yoshimura, R	1
Castellano, GM; Garbuzenko, OB; Malhotra, J; Minko, T; Pine, SR; Sabaawy, HE; Zeeshan, S	1

Reviews

4 review(s) available for pyrazines and paclitaxel

Article	Year
New drugs in gynecologic cancer. Current treatment options in oncology, 2001, Volume: 2, Issue:2 Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab	2001
New developments in chemotherapy for advanced non-small cell lung cancer. Current opinion in oncology, 2006, Volume: 18, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epothilones; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Pyrazines	2006
[Peripheral neuropathy induced by anticancer drugs]. Fukuoka igaku zasshi = Hukuoka acta medica, 2013, Volume: 104, Issue:5 Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cold Temperature; Drugs, Chinese Herbal; Humans; Hyperalgesia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sensation Disorders; Vincristine; Vitamin B 12	2013
Rodent models of chemotherapy-induced peripheral neuropathy. ILAR journal, 2014, Volume: 54, Issue:3 Topics: Animals; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Mice; Nerve Degeneration; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Rats; Vincristine	2014

Trials

9 trial(s) available for pyrazines and paclitaxel

Article	Year
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome	2007
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Cardia; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Paclitaxel; Pyrazines; Stomach Neoplasms; Survival Rate; Treatment Outcome	2008
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:13 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome	2008
Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Early Termination of Clinical Trials; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Postoperative Complications; Protease Inhibitors; Pyrazines; Radiotherapy; Respiratory Insufficiency	2010
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome	2010
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer, 2010, Jul-15, Volume: 116, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrazines; Skin Neoplasms	2010
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Molecular cancer therapeutics, 2011, Volume: 10, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome	2011
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pyrazines; Survival Analysis	2015
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic oncology, 2018, Volume: 149, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult	2018

Other Studies

28 other study(ies) available for pyrazines and paclitaxel

Article	Year
Interactions of a new antimitotic agent, NSC-181928, with purified tubulin. Biochemical and biophysical research communications, 1982, Feb-11, Volume: 104, Issue:3 Topics: Alkaloids; Animals; Benzimidazoles; Carbamates; Cattle; Colchicine; Guanosine Triphosphate; Hydrolysis; Nocodazole; Paclitaxel; Polymers; Pyrazines; Temperature; Tubulin	1982
Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anti-cancer drugs, 1995, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cell Division; Colchicine; Demecolcine; Docetaxel; Humans; KB Cells; Microscopy, Fluorescence; Microscopy, Immunoelectron; Microtubule Proteins; Microtubules; Paclitaxel; Pyrazines; Pyridines; Taxoids; Tubulin	1995
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma]. Bulletin du cancer, 1994, Volume: 81, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine	1994
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia, 2001, Volume: 15, Issue:6 Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Cyclosporins; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Epoxy Compounds; Flavonoids; Hematopoietic Stem Cells; HL-60 Cells; Humans; Jurkat Cells; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Paclitaxel; Piperidines; Poly(ADP-ribose) Polymerases; Pyrazines; Substrate Specificity; Thiazoles	2001
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene, 2002, Sep-19, Volume: 21, Issue:42 Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Differentiation; Cell Division; Chloramphenicol O-Acetyltransferase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation; HeLa Cells; Humans; I-kappa B Proteins; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Promoter Regions, Genetic; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrophosphatases; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation	2002
Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia, 2004, Volume: 18, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Division; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Synergism; Humans; Lymphoma; Membrane Glycoproteins; NF-kappa B; Paclitaxel; Pleural Effusion, Malignant; Pyrazines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha	2004
VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene, 2005, Feb-24, Volume: 24, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; Cell Survival; Genes, Tumor Suppressor; Humans; Kidney Neoplasms; NF-kappa B; Paclitaxel; Pyrazines; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2005
Emerging advances in the management of lung cancer. Clinical lung cancer, 2004, Volume: 6 Suppl 2 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Paclitaxel; Polyglutamic Acid; Protease Inhibitors; Pyrazines; Taxoids	2004
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer cell, 2005, Volume: 7, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation; Genes, ras; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Neoplasms, Glandular and Epithelial; Paclitaxel; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Suppressor Protein p53	2005
Lung cancer - Second Annual Winter Conference. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:5 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines	2005
Genotypic guidance for chemotherapy choices. Drug discovery today, 2005, May-01, Volume: 10, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genotype; Humans; Membrane Proteins; Paclitaxel; Protease Inhibitors; Proto-Oncogene Proteins; Pyrazines	2005
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer]. Revue de pneumologie clinique, 2006, Volume: 62 Spec no 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A	2006
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16 Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays	2008
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Investigational new drugs, 2009, Volume: 27, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Stress; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Ovarian Neoplasms; Paclitaxel; Protein Array Analysis; Pyrazines; Stress, Physiological; Time Factors; Up-Regulation	2009
[Proteasome inhibitors sensitize ovarian cancer cells to paclitaxel induced apoptosis]. Zhonghua fu chan ke za zhi, 2008, Volume: 43, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction	2008
Combination effects of SC144 and cytotoxic anticancer agents. Anti-cancer drugs, 2009, Volume: 20, Issue:5 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytotoxins; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Injections, Intraperitoneal; Mice; Mice, Nude; Organoplatinum Compounds; Paclitaxel; Pyrazines; Quinoxalines; Xenograft Model Antitumor Assays	2009
Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Experimental neurology, 2010, Volume: 226, Issue:2 Topics: Analysis of Variance; Animals; Antineoplastic Agents; Body Weight; Boronic Acids; Bortezomib; Cisplatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Ganglia, Spinal; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nerve Fibers, Myelinated; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Sciatic Nerve	2010
Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. Oncology reports, 2013, Volume: 29, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carboplatin; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Membrane Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Paclitaxel; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Uterine Cervical Neoplasms	2013
Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain, 2013, Volume: 154, Issue:11 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Axons; Boronic Acids; Bortezomib; Energy Metabolism; Hyperalgesia; Male; Mitochondria; Neoplasm Transplantation; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nerves; Peroxynitrous Acid; Physical Stimulation; Protein Processing, Post-Translational; Pyrazines; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Superoxide Dismutase	2013
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Humans; Mice; Mice, Nude; Odds Ratio; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1	2013
Novel facts about FAK: new connections to drug resistance? Journal of the National Cancer Institute, 2013, Oct-02, Volume: 105, Issue:19 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Humans; Organic Chemicals; Ovarian Neoplasms; Paclitaxel; Pyrazines; Sulfonamides; Y-Box-Binding Protein 1	2013
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells. PloS one, 2013, Volume: 8, Issue:10 Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles	2013
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. The international journal of biochemistry & cell biology, 2014, Volume: 51 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Interactions; Drug Resistance, Multiple; HEK293 Cells; Humans; Imidazoles; Lung Neoplasms; Mitoxantrone; Models, Molecular; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Pyrazines	2014
Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Scientific reports, 2014, Sep-18, Volume: 4 Topics: Action Potentials; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Behavior, Animal; Boronic Acids; Bortezomib; Cisplatin; Electrophysiology; Gait; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Polyneuropathies; Pyrazines; Vincristine	2014
Pharmacological interventions targeting Wnt/β-catenin signaling pathway attenuate paclitaxel-induced peripheral neuropathy. European journal of pharmacology, 2019, Dec-01, Volume: 864 Topics: Animals; Behavior, Animal; Depsipeptides; Gene Expression Regulation; Male; Paclitaxel; Peripheral Nervous System Diseases; Pyrazines; Pyridines; Rats; Rats, Sprague-Dawley; Sciatic Nerve; Wnt Signaling Pathway	2019
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome. Cancer science, 2020, Volume: 111, Issue:12 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Decitabine; G2 Phase; Heterografts; HL-60 Cells; Humans; Mice; Myelodysplastic Syndromes; Paclitaxel; Pyrazines; Sequence Analysis, RNA; Tubulin; Tubulin Modulators; Vincristine	2020
Mechanotransduction-Targeting Drugs Attenuate Stiffness-Induced Hepatic Stellate Cell Activation in Vitro. Biological & pharmaceutical bulletin, 2021, Mar-01, Volume: 44, Issue:3 Topics: Actins; Adenosine Triphosphate; Animals; Benzamides; Cells, Cultured; Colchicine; Collagen Type I; Hepatic Stellate Cells; Imidazoles; Integrins; Male; Mechanotransduction, Cellular; Paclitaxel; Piperazines; Pyrazines; Quinoxalines; Rats, Sprague-Dawley; Roscovitine; Sulfonamides; Transforming Growth Factor beta; Tubulin Modulators	2021
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Molecular cancer therapeutics, 2022, 09-06, Volume: 21, Issue:9 Topics: Animals; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; DNA; Humans; Lung; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases; Triazoles	2022